NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) News Today $8.35 -0.04 (-0.48%) (As of 02:27 PM ET) Add Compare Share Share Today's Range$8.30▼$8.4950-Day Range$7.37▼$8.7752-Week Range$7.20▼$15.43Volume895,936 shsAverage Volume2.93 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice Target$15.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.350.49▲Average Medical News Sentiment BCRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼33▲BCRX Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congressfinance.yahoo.com - May 31 at 9:29 AMBioCryst Pharmaceuticals: An Updated Viewseekingalpha.com - May 31 at 3:44 AMGW&K Investment Management LLC Has $19.83 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - May 26 at 9:14 AMRussell Investments Group Ltd. Buys 23,818 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - May 23 at 4:43 AMTekla Capital Management LLC Acquires 323,135 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - May 22 at 11:10 AMBioCryst Pharma Receives Approval Of ORLADEYO From Public Health Institute Of Chilemarkets.businessinsider.com - May 22 at 10:42 AMBioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chilefinance.yahoo.com - May 22 at 10:42 AMVictory Capital Management Inc. Sells 986,833 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - May 21 at 5:52 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Artisan Partners Limited Partnershipmarketbeat.com - May 19 at 9:37 AMCommonwealth Equity Services LLC Has $1.78 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - May 18 at 4:35 AMBrokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.00americanbankingnews.com - May 14 at 4:16 AMBioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded by StockNews.com to Holdamericanbankingnews.com - May 14 at 3:37 AMReviewing BioCryst Pharmaceuticals (NASDAQ:BCRX) and ImmunityBio (NASDAQ:IBRX)americanbankingnews.com - May 12 at 3:26 AMBioCryst Pharmaceuticals (NASDAQ:BCRX) Lowered to Hold at StockNews.commarketbeat.com - May 12 at 1:20 AMBioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) institutional shareholders had a great week as one-year returns increased after a 13% gain last weekfinance.yahoo.com - May 9 at 12:56 PMQ2 2023 Earnings Estimate for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Issued By HC Wainwrightamericanbankingnews.com - May 9 at 2:40 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analystsmarketbeat.com - May 9 at 1:40 AMBioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to "Buy" at StockNews.comamericanbankingnews.com - May 8 at 5:00 AMQ2 2023 EPS Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reduced by Analystmarketbeat.com - May 8 at 2:33 AMHC Wainwright Comments on BioCryst Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:BCRX)marketbeat.com - May 5 at 8:43 AMBioCryst gains 14% most since February after Q1 2023 resultsmsn.com - May 3 at 5:24 PMBioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcriptfinance.yahoo.com - May 3 at 5:24 PMBioCryst Clocks 37.8% Revenue Growth In Q1 On Solid New Patient Growthmsn.com - May 3 at 12:23 PMBioCryst Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentationseekingalpha.com - May 3 at 8:58 AMBioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66Mmsn.com - May 3 at 7:23 AMBioCryst Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 3 at 7:23 AMState of New Jersey Common Pension Fund D Acquires 22,658 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - April 28 at 5:08 AMBioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)finance.yahoo.com - April 27 at 7:56 AMBioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Wednesdayamericanbankingnews.com - April 26 at 6:32 AMBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from Needham & Company LLCamericanbankingnews.com - April 24 at 3:24 AMEvercore ISI Trims BioCryst Pharmaceuticals (NASDAQ:BCRX) Target Price to $10.00americanbankingnews.com - April 23 at 2:48 AMPharma with Bham presence takes $300M loan to pay down debtbizjournals.com - April 21 at 5:09 AMEvercore ISI Group Maintains Biocryst Pharmaceuticals (BCRX) Outperform Recommendationmsn.com - April 20 at 10:35 PMNeedham Reiterates Biocryst Pharmaceuticals (BCRX) Buy Recommendationmsn.com - April 20 at 10:35 PMDurham pharma takes $300M loan to pay down debtbizjournals.com - April 20 at 12:34 PMBioCryst to Report First Quarter 2023 Financial Results on May 3finance.yahoo.com - April 19 at 10:55 AMAnalysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $16.43americanbankingnews.com - April 19 at 3:55 AMWhy Is BioCryst Pharmaceuticals (BCRX) Stock Down 8% Today?markets.businessinsider.com - April 18 at 1:00 PMBioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakonfinance.yahoo.com - April 18 at 7:59 AMLacklustre Performance Is Driving BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/Sfinance.yahoo.com - April 17 at 4:58 PMBCRX BioCryst Pharmaceuticals, Inc.seekingalpha.com - April 15 at 8:40 AMThe Big Short: 5 Stocks At Risk With High Short Interestseekingalpha.com - April 12 at 6:00 AMRobert Ingram, pillar of Triangle pharma industry, diesbizjournals.com - March 30 at 8:09 AMBioCryst Celebrates Bob Ingram’s Contributions to the Company’s Successfinance.yahoo.com - March 29 at 8:55 PMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.13 Consensus Price Target from Brokeragesamericanbankingnews.com - March 23 at 3:54 AMAssenagon Asset Management S.A. Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - March 22 at 5:28 AMBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - March 20 at 2:15 AMNorth Star Investment Management Corp. Has $4.22 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - March 19 at 9:43 AMBioCryst's Commercialization Of Orladeyo: Risks Materializing, A Shorting Opportunityseekingalpha.com - March 16 at 5:50 PMEngineers Gate Manager LP Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)marketbeat.com - March 9 at 6:42 AM Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NVAX News Today AGEN News Today HALO News Today EXEL News Today VCEL News Today KYMR News Today RXRX News Today RLAY News Today PRME News Today SANA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:BCRX) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.